Steatosis is the predictor of relapse in HCV genotype 3- But not 2-infected patients treated with 12 weeks of pegylated interferon-α-2a plus ribavirin and RVR

Journal of Viral Hepatitis

Volumn 19, Issue 5, 2012, Pages 346-353

  Restivo, L ^a   Zampino, R ^a   Guerrera, B ^a   Ruggiero, L ^a   Adinolfi, Luigi E ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

12 weeks therapeutic regimen; Genotype 2 3; HCV infection; Peg IFN ribavirin; Steatosis

Indexed keywords

PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; CONTROLLED STUDY; FATTY LIVER; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RELAPSE; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD;

EID: 84859813231     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2011.01555.x     Document Type: Article

References (39)

1. Ghany MG, Strader DB, Thomas DL et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374.
2. Dalgard O, Bjoro K, Hellum KB et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004; 40: 1260-1265. (Pubitemid 39656999)
3. Dalgard O, Bjoro K, Ring-Larsen H et al. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 2008; 47: 35-42. (Pubitemid 351171039)
4. Lagging M, Langeland N, Pedersen C et al. Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology 2008; 47: 1837-1845. (Pubitemid 351945551)
5. Mangia A, Santoro R, Minerva N et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352: 2609-2617. (Pubitemid 41007847)
6. Shiffman ML, Suter F, Bacon BR et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357: 124-134. (Pubitemid 47057730)
7. Yu ML, Dai CY, Huang JF et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007; 56: 553-559.
8. Bressler BL, Guindi M, Tomlinson G et al. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003; 38: 639-644. (Pubitemid 37052150)
9. Adinolfi LE, Utili R, Andreana A et al. Serum HCV RNA levels correlate with histological liver damage and concur with steatosis in progression of chronic hepatitis C. Dig Dis Sci 2001; 46: 1677-1683. (Pubitemid 32727098)
10. Asselah T, Rubbia-Brandt L, Marcellin P et al. Steatosis in chronic hepatitis C: why does it really matter? Gut 2006; 55: 123-130. (Pubitemid 41820647)
11. Bochud PY, Cai T, Overbeck K et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol 2009; 51: 655-666.
12. Hissar SS, Goyal A, Kumar M et al. Hepatitis C virus genotype 3 predominates in North and Central India and is associated with significant histopathologic liver disease. J Med Virol 2006; 78: 452-458. (Pubitemid 43346895)
13. von Wagner M, Huber M, Berg T et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129: 522-527. (Pubitemid 41096640)
14. Andriulli A, Mangia A, Iacobellis A et al. Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther 2008; 28: 397-404. (Pubitemid 352033287)
15. Zeuzem S, Hultcrantz R, Bourliere M et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40: 993-999. (Pubitemid 38670134)
16. Balkau B, Charles MA. Comments on the provisional report from the WHO consultation. Diabet Med 1999; 16: 442-443.
17. Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699.
18. Diago M, Shiffman ML, Bronowicki JP et al. Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin. Hepatology 2010; 51: 1897-1903.
19. Mangia A, Bandiera F, Montalto G et al. Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3. J Hepatol 2010; 53: 1000-1005.
20. De Compadri P, Koleva D, Mangia A et al. Cost minimisation analysis of 12 or 24 weeks of peginterferon alfa-2b + ribavirin for hepatitis C virus. J Med Econ 2008; 11: 151-163. (Pubitemid 351613820)
21. Mecenate F, Pellicelli AM, Barbaro G et al. Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial. BMC Gastroenterol 2010; 10: 21.
22. Mangia A, Minerva N, Bacca D et al. Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection. Hepatology 2009; 49: 358-363.
23. Shah SR, Patel K, Marcellin P et al. Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3. Clin Gastroenterol Hepatol 2011; 9: 688-693.
24. Poynard T, Ratziu V, McHutchison J et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003; 38: 75-85. (Pubitemid 36775798)
25. Patton HM, Patel K, Behling C et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004; 40: 484-490. (Pubitemid 38230851)
26. Negro F, Clement S. Impact of obesity, steatosis and insulin resistance on progression and response to therapy of hepatitis C. J Viral Hepat 2009; 16: 681-688.
27. Lonardo A, Lombardini S, Scaglioni F et al. Hepatic steatosis and insulin resistance: does etiology make a difference? J Hepatol 2006; 44: 190-196. (Pubitemid 41772534)
28. Adinolfi LE, Gambardella M, Andreana A et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-1364. (Pubitemid 32496971)
29. Quadri R, Rubbia-Brandt L, Abid K et al. Detection of the negative-strand hepatitis C virus RNA in tissues: implications for pathogenesis. Antiviral Res 2001; 52: 161-171. (Pubitemid 32973691)
30. Asselah T, Martinot M, Cazals-Hatem D et al. Hypervariable region 1 quasispecies in hepatitis C virus genotypes 1b and 3 infected patients with normal and abnormal alanine aminotransferase levels. J Viral Hepat 2002; 9: 29-35. (Pubitemid 36002484)
31. Pazienza V, Clement S, Pugnale P et al. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology 2007; 45: 1164-1171. (Pubitemid 46775778)
32. Zografos TA, Liaskos C, Rigopoulou EI et al. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C. Am J Gastroenterol 2008; 103: 605-614. (Pubitemid 351406003)
33. Abe H, Ochi H, Maekawa T et al. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J Hepatol 2010; 53: 439-443.
34. McCarthy JJ, Li JH, Thompson A et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010; 138: 2307-2314.
35. Mangia A, Thompson AJ, Santoro R et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010; 139: 821-827.
36. Moghaddam A, Melum E, Reinton N et al. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology 2011; 53: 746-754.
37. Valenti L, Rumi M, Galmozzi E et al. Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology 2011; 53: 791-799.
38. Cai T, Dufour JF, Muellhaupt B et al. Viral genotype-specific role of PNPLA3, PPARG, MTTP, and IL28B in hepatitis C virus-associated steatosis. J Hepatol 2011; 55: 529-535.
39. Craxi A, Pawlotsky JM, Wedemeyer H et al. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-264.